Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Tempest Therapeutics, Inc.MLND · Entity 7734 | Sec., CAO and General Counsel | January 15, 2019 | January 17, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Tempest Therapeutics, Inc.
Report date January 15, 2019 · Filed January 17, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.80 · Expires 2029-01-14 | Direct | 56,000 |
Reported balance
After 2019-01-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-01-15 · Grant · Acquired 56,000 · Balance 56,000 F1: Twenty-five percent (25%) of the shares subject to this option shall vest on January 15, 2020, and one thirty-sixth (1/36th) of the remaining shares subject to this option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Twenty-five percent (25%) of the shares subject to this option shall vest on January 15, 2020, and one thirty-sixth (1/36th) of the remaining shares subject to this option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 15, 2019 Filed Jan 17, 2019 16:44 UTC | Tempest Therapeutics, Inc. MLND · Entity 7734 | GrantEmployee Stock Option (right to buy) · Derivative | 56,000 | $0.00 Strike: $8.80 | $0.00 |
DisclosureSEC source: 0001209191-19-004228 · doc4.xml · derivative · entry 1 Brinza Jeffery M. · CIK 0001760214 · Sec., CAO and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,000 Underlying: Common Stock · 56,000 shares Expires 2029-01-14 F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to this option shall vest on January 15, 2020, and one thirty-sixth (1/36th) of the remaining shares subject to this option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| December 07, 2018 Filed Dec 11, 2018 19:36 UTC | Tempest Therapeutics, Inc. MLND · Entity 7734 | GrantEmployee Stock Option (right to buy) · Derivative | 44,639 | Not disclosed Strike: $16.40 | Not disclosed |
DisclosureSEC source: 0001209191-18-062106 · doc4.xml · derivative · entry 2 Brinza Jeffery M. · CIK 0001760214 · Sec., CAO and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,639 Underlying: Common Stock · 44,639 shares Expires 2028-08-23 F4 · price: Received in connection with the Merger in exchange for a stock option to acquire 600,000 shares of Millendo common stock for $1.22 per share. F3 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option shall vest on August 20, 2019, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| December 07, 2018 Filed Dec 11, 2018 19:36 UTC | Tempest Therapeutics, Inc. MLND · Entity 7734 | GrantEmployee Stock Option (right to buy) · Derivative | 49,609 | Not disclosed Strike: $4.44 | Not disclosed |
DisclosureSEC source: 0001209191-18-062106 · doc4.xml · derivative · entry 1 Brinza Jeffery M. · CIK 0001760214 · Sec., CAO and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,609 Underlying: Common Stock · 49,609 shares Expires 2026-01-27 F2 · price: Received in connection with the merger of Millendo Therapeutics, Inc. ("Millendo") into the Issuer (the "Merger") in exchange for a stock option to acquire 666,800 shares of Millendo common stock for $0.33 per share. F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option vested on August 24, 2016, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.